Journal article · 2026 · Open access
Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials
Nature Medicine · Published 3 November 2026 · DOI 10.1038/s41591-026-04743-6
In brief
“Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials” is a 2026 journal article by Rodabe Navroze Amaria and 17 co-authors, published in Nature Medicine. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Medicine.
- Citations
- 0
- References
- 31
- Authors
- 18
Abstract
Amsokigene autoleucel (amsoki-cel, OBX-115) is a tumor-infiltrating lymphocyte (TIL) cell therapy engineered to express acetazolamide (ACZ)-regulatable membrane-bound interleukin-15, abrogating the need for interleukin-2. In two single-arm trials (completed phase 1 single-center first-in-human (FIH) and ongoing phase 1/2 multicenter Agni-01), patients with immune checkpoint inhibitor (ICI)-resistant advanced melanoma received lymphodepletion and varying doses and schedules of amsoki-cel and ACZ. The primary objective of FIH and Agni-01 phase 1 was safety, tolerability and recommended phase 2 dose (RP2D); the primary objective of Agni-01 phase 2 was objective response rate (ORR) at the RP2D. The first patient treated experienced rapid lymphocyte expansion and vasogenic edema of a previously irradiated brain metastasis, prompting protocol modifications and dose deescalation in FIH, including 80% reduction in maximum amsoki-cel dose and 75% reduction in ACZ dose. After preliminary demonstration of safety at the lower dose, doses were increased in FIH, and reescalation was initiated in Agni-01. Across studies, 37 patients were treated (FIH, n = 17; Agni-01, n = 20). Post hoc pooled analysis demonstrated no dose-limiting toxicities, ICU care or treatment-related mortality. Most common grade 3 or higher treatment-emergent adverse events (TEAEs) included neutropenia (64.9% (24/37)), leukopenia/lymphopenia (56.8% (21/37) each) and anemia/thrombocytopenia (37.8% (14/37) each). Serious TEAEs were reported for 10 patients, including eight patients with grade 3 or higher events (non-hematologic, 13.5% (5/37); hematologic, 13.5% (5/37)). RP2D was selected based on overall safety and tolerability as well as preliminary anti-tumor activity in Agni-01 phase 1. The phase 2 preliminary ORR was 66.7% (6/9). In total, 15 patients were treated at RP2D and comprise the Key Efficacy Set (Agni-01: phase 1, n = 6; phase 2, n = 9), of which 10 patients (66.7%; 95% confidence interval 38-88%) achieved objective responses (including two complete responses). Amsoki-cel demonstrated favorable safety and promising early clinical activity in patients with ICI-resistant melanoma. A separate phase 2 pivotal Agni-01 cohort is ongoing. ClinicalTrials.gov identifiers: NCT05470283 and NCT06060613 .
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Amaria, R. N., Chesney, J. A., Warner, A. B., In, G. K., Shoushtari, A. N., Johnson, T. T., Hamid, O., Samhouri, Y., Davies, M. A., Tawbi, H. A., Oliva, I. C. G., Aksoy, B. A., Kelly, A., Duan, R., Prabhakar, P., Ramsingh, G., Jagasia, M., & Hari, P. (2026). Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials. Nature Medicine. https://doi.org/10.1038/s41591-026-04743-6
MLA 9
Amaria, Rodabe Navroze, et al. “Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.” Nature Medicine, 2026. https://doi.org/10.1038/s41591-026-04743-6.
Chicago
Amaria, Rodabe Navroze, Jason Alan Chesney, Allison Betof Warner, Gino Kim In, Alexander Noor Shoushtari, Tirrell T. Johnson, Omid Hamid, et al. 2026. “Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials.” Nature Medicine. https://doi.org/10.1038/s41591-026-04743-6.
Harvard
Amaria, R. N. et al. (2026) ‘Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials’, Nature Medicine. doi:10.1038/s41591-026-04743-6.
IEEE
R. N. Amaria et al., “Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials,” Nature Medicine, 2026, doi: 10.1038/s41591-026-04743-6.
BibTeX
@article{amaria2026regulatable,
title = {{Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials}},
author = {Amaria, Rodabe Navroze and Chesney, Jason Alan and Warner, Allison Betof and In, Gino Kim and Shoushtari, Alexander Noor and Johnson, Tirrell T. and Hamid, Omid and Samhouri, Yazan and Davies, Michael A. and Tawbi, Hussein A. and Oliva, Isabella C. Glitza and Aksoy, Bülent Arman and Kelly, Amanda and Duan, Raina and Prabhakar, Prakash and Ramsingh, Giridharan and Jagasia, Madan and Hari, Parameswaran},
journal = {Nature Medicine},
year = {2026},
doi = {10.1038/s41591-026-04743-6},
url = {https://doi.org/10.1038/s41591-026-04743-6}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- tumor-infiltrating lymphocytes
- acetazolamide
- immune checkpoint inhibitor resistance
- advanced melanoma
- lymphocyte depletion
- dose-limiting toxicity
- neutropenia
- objective response rate
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Amaria, R. N., Chesney, J. A., Warner, A. B., In, G. K., Shoushtari, A. N., Johnson, T. T., Hamid, O., Samhouri, Y., Davies, M. A., Tawbi, H. A., Oliva, I. C. G., Aksoy, B. A., Kelly, A., Duan, R., Prabhakar, P., Ramsingh, G., Jagasia, M., & Hari, P. (2026). Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials. Nature Medicine. https://doi.org/10.1038/s41591-026-04743-6
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.
Who wrote this paper?
Rodabe Navroze Amaria, Jason Alan Chesney, Allison Betof Warner, Gino Kim In, Alexander Noor Shoushtari, Tirrell T. Johnson, Omid Hamid, Yazan Samhouri, Michael A. Davies, Hussein A. Tawbi, Isabella C. Glitza Oliva, Bülent Arman Aksoy and 6 more.
What is the DOI of this paper?
10.1038/s41591-026-04743-6, permanently at https://doi.org/10.1038/s41591-026-04743-6. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.